The US Food and Drug Administration is speeding up approval of HYRNUO® by Bayer as a first-line targeted therapy for patients with HER2-mutated non-small cell lung cancer.

Zhitongcaijing · 2d ago
The US Food and Drug Administration is speeding up approval of HYRNUO® by Bayer as a first-line targeted therapy for patients with HER2-mutated non-small cell lung cancer.